# Compare the Question, Not Just the Number

> Compare Metabolic Peptide Evidence — Medical Peptides Literature Review — Compare four Metabolic & Weight research peptides by mechanism, studied population, evidence maturity, endpoints, safety signals, and what each design can establish.

**EVIDENCE MATRIX / FOUR FILES**

Mechanism, population, endpoint, and evidence maturity determine whether results can be compared—and what conclusions survive the comparison.

## Start with the study question

These four compounds are often grouped under “metabolic peptides,” but they do not answer one shared clinical question. Semaglutide and tirzepatide are incretin-based approved medicines with large diabetes and weight programs [5][6]. Tesamorelin stimulates the growth hormone axis and was tested for excess abdominal fat in adults with HIV-associated lipodystrophy [11][15]. Retatrutide is a triple-receptor investigational agent with phase 2 results [17][20].

A fair comparison starts by asking what the investigators measured. Whole-body weight change is not the same as visceral-fat area, liver-fat fraction, a cardiovascular event, or a kidney composite. A placebo-controlled trial estimates an effect against no active treatment; a head-to-head trial directly compares options within one protocol; a safety review integrates a broader record; a community report describes experience without proving cause.

The table below is therefore an evidence map, not a winner board. It shows where direct comparison is strong, where only indirect context is available, and where later trials still have to do the work.

## Evidence matrix

| Compound | Main receptor system | Best-established studied frame | Evidence maturity | What the current record can establish |
|---|---|---|---|---|
| **Semaglutide** | GLP-1 receptor | Weight management plus cardiovascular and kidney outcomes in defined high-risk groups | Approved; large pivotal and outcome trials; post-approval safety record | Causal efficacy for studied endpoints, including weight change, cardiovascular events, and kidney outcomes [2][3][4] |
| **Tirzepatide** | GIP + GLP-1 receptors | Type 2 diabetes and chronic weight management | Approved; phase 3 programs; direct active comparison; growing surveillance | Strong weight and glucose efficacy, including greater mean weight loss than semaglutide in SURMOUNT-5 [1][8][9] |
| **Tesamorelin** | GHRH receptor and downstream GH/IGF-1 axis | Excess abdominal fat in adults with HIV-associated lipodystrophy | Approved for a focused indication; pivotal and follow-up trials; pooled analysis | Reduction in visceral adipose tissue in the studied HIV population, with evidence on hepatic fat and reaccumulation after withdrawal [10][12][14][15] |
| **Retatrutide** | GIP + GLP-1 + glucagon receptors | Investigational obesity, type 2 diabetes, and metabolic liver-disease studies | Phase 2 published; phase 3 confirmation pending | Large preliminary signals in weight, glucose, and liver fat, without an approved or post-approval record [19][20][21] |

## Where direct comparisons hold

The strongest direct comparison on this desk is SURMOUNT-5 [1]. It placed tirzepatide and semaglutide inside the same 72-week protocol in 751 adults with obesity but without type 2 diabetes [1]. Mean weight change was -20.2% with tirzepatide and -13.7% with semaglutide [1]. Because the population, calendar, and assessment framework were shared, the inference is cleaner than comparing separate placebo-controlled programs.

That result is still endpoint-bound. It establishes greater mean weight reduction under the trial conditions. It does not show that tirzepatide has superior kidney or cardiovascular outcomes; semaglutide's FLOW and SELECT trials directly tested those different questions [2][3]. SURPASS-2 also directly compared tirzepatide with semaglutide in adults with type 2 diabetes, finding larger glucose and weight reductions for tirzepatide at the studied regimens over 40 weeks [9].

Tesamorelin and retatrutide do not belong in those direct rankings. Tesamorelin trials measured visceral-fat change in HIV lipodystrophy [12][15]. Retatrutide's phase 2 program has no completed head-to-head trial against the approved drugs in this reference set [17][20].

## Safety evidence changes with maturity

Common adverse effects can appear in pivotal trials; uncommon events and patterns may require far more exposure. Semaglutide has the broadest mature safety literature here, with gastrointestinal intolerance and biliary disease established while some cancer signals remain unresolved [5]. Tirzepatide has pooled randomized evidence showing an increased composite gallbladder or biliary risk but no statistically significant pancreatitis increase in that analysis [7].

Tesamorelin's key cautions follow its GH/IGF-1 mechanism, focused indication, and limited long-term generalizability. Its liver-safety monograph found it unlikely to cause clinically apparent liver injury, while pathway-specific concerns remain relevant [11]. Retatrutide's phase 2 trials identify gastrointestinal events and a dose-dependent heart-rate increase, but cannot yet supply rare-event or long-duration certainty [20][21].

Real-world sources serve different functions after that. Spontaneous reports can generate safety signals but often lack a reliable denominator. Routine-care cohorts can test effectiveness in less selected populations but remain vulnerable to confounding. Community reports are anecdotal, not clinical evidence; they are useful for hearing what participants notice, not for calculating incidence or making causal claims.

## The responsible takeaway

Evidence maturity is not a synonym for effect size. Semaglutide's chief strength on this desk is breadth: multiple large outcome programs and a mature safety discussion [2][3][5]. Tirzepatide's distinctive strength is direct comparative efficacy within a robust phase 3 program [1][8][9]. Tesamorelin's strength is specificity: trials repeatedly address visceral fat in a defined HIV-lipodystrophy population [10][14][15]. Retatrutide's strength is the size and consistency of its early metabolic signals, paired with a large remaining confirmation burden [17][19][20][21].

The most defensible comparison preserves those differences. It avoids importing a trial result into an unstudied population, avoids treating a surrogate as a clinical outcome, and avoids turning a surveillance signal into a proven causal effect. That discipline is the difference between a list of impressive numbers and a usable literature review.

---

This independent desk reviews metabolic-peptide evidence from pivotal trials through real-world surveillance; it is neither clinical counsel nor a marketplace.